Clinical Trials Logo

Clinical Trial Summary

Glutamine is the most abundant nonessential amino acid in the human body. Besides its role as a constituent of proteins and its importance in amino acid transamination, glutamine may modulate immune cells.

The innate immune system is the first line of host defence against pathogens and in most cases sufficient to eliminate invading microbes. Mammalian Toll-like receptors (TLR) comprise a family of germ line-encoded trans-membrane receptors which activation leads to the induction of inflammatory responses, phagocytosis but also to the development of antigen specific adapative immunity.

It has been postulated though not formally proven yet that glutamine beneficial effect could be due to a positive effect on the innate immune system. Given the importance of TLRs and TLRs-dependent signalling in host defence against infections we hypothesized that glutamine may increase the expression and/or functionality of TLRs which in turn may have beneficial effects to clear infections.


Clinical Trial Description

Objective: To evaluate whether glutamine supplementation alters the expression and functionality of TLR2 and TLR4 in circulating monocytes of trauma patients admitted to the ICU. Specifically the next variables were measured:

- Expression of TLR2 and TLR4 in peripheral blood monocytes was determined by flow cytometry

- To study the functionality of TLR2 and TLR4, monocytes were stimulated with TLR specific agonists and cytokines were measured in cell culture supernatants. We determined the concentration of IL-1β, IL-6, TNFα and IL-10 in cell culture supernatants using a bead array ELISA.

- To determine the phagocytic capability of monocytes, live Escherichia coli expressing green fluorescent protein was added to 100 μL of whole blood collected in K2-anticoagulation medium tubes. Bacteria were added at a ratio of 100 bacteria per monocyte. The analyses were carried out in an Epics XL flow cytometer. ;


Study Design

Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Masking: Single Blind (Outcomes Assessor)


Related Conditions & MeSH terms

  • Injury Severity Score (ISS) > 12 Points Were Included in the Study.
  • Moderate to Severe Trauma, as Defined by an

NCT number NCT01250080
Study type Interventional
Source Hospital Universitari Son Dureta
Contact
Status Completed
Phase N/A
Start date January 2007
Completion date September 2008